Grade My Investments
HomeFree Stock Grades › OLMA

Olema Pharmaceuticals, Inc. (OLMA) Stock Grade

OLMA · Healthcare

B
Grade updated: July 18, 2026
Computed by the GradeMyInvestments scoring model from revenue growth, profitability, balance-sheet strength, and analyst targets.
Market Cap
$2.2B
P/E Ratio
Revenue Growth (YoY)
0.0%
Net Margin
0.0%
Return on Equity
Dividend Yield
None

About Olema Pharmaceuticals, Inc.'s fundamentals

Olema Pharmaceuticals is a biotechnology company with a market capitalization of $2.2 billion that reported flat revenue growth year-over-year at 0.0%. The company posted a net loss in its latest annual statement, resulting in a net margin of 0.0%, and currently does not pay a dividend to shareholders. As a pre-profitability biotech firm, traditional valuation metrics like P/E ratio and return on equity are not applicable.

Track OLMA free — no credit card required. Live grade + monthly AI report →